Vogenx sets IPO price at $13 per share, targets $81.3M proceeds
Biotech firm Vogenx priced its IPO at $13 per share, with proceeds expected to total $81.3 million. The offering is scheduled to list on the Nasdaq under the ticker VGEN.
Vogenx Inc. priced its initial public offering at $13 per share, according to a regulatory filing.
The biotechnology company expects gross proceeds of approximately $81.3 million from the offering, with the shares set to begin trading on the Nasdaq exchange under the ticker symbol VGEN.
The IPO price was finalized after the company and its underwriters concluded the pricing process. The proceeds will be used for research and development, clinical trials and general corporate purposes, the filing stated.
Underwriters for the offering include Cowen and Company, William Blair and Leerink Partners, which will act as joint book-running managers. Additional details regarding the offering size and allocation were not disclosed in the filing.
Vogenx, based in Cambridge, Massachusetts, focuses on developing therapies in the biotech sector. The company has not yet provided further commentary on the IPO timing or market conditions influencing the pricing decision.
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
Plus de Sophie Laurent →